Immunome (NASDAQ:IMNM – Get Free Report) and Arcellx (NASDAQ:ACLX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Insider and Institutional Ownership
44.6% of Immunome shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 7.7% of Immunome shares are owned by insiders. Comparatively, 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations and price targets for Immunome and Arcellx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunome | 1 | 0 | 10 | 0 | 2.82 |
| Arcellx | 1 | 1 | 8 | 1 | 2.82 |
Risk & Volatility
Immunome has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
Earnings and Valuation
This table compares Immunome and Arcellx”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunome | $9.04 million | 146.74 | -$292.96 million | ($3.08) | -4.95 |
| Arcellx | $107.94 million | 46.36 | -$107.35 million | ($3.93) | -22.02 |
Arcellx has higher revenue and earnings than Immunome. Arcellx is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Immunome and Arcellx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunome | -1,687.08% | -77.37% | -66.66% |
| Arcellx | -607.01% | -51.13% | -33.09% |
Summary
Arcellx beats Immunome on 8 of the 14 factors compared between the two stocks.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
About Arcellx
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
